<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971812</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01</org_study_id>
    <secondary_id>2019-A00145-52</secondary_id>
    <secondary_id>RCAPHM19_0001</secondary_id>
    <nct_id>NCT03971812</nct_id>
  </id_info>
  <brief_title>Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma</brief_title>
  <acronym>GLIOMANOID</acronym>
  <official_title>Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study research proposal is to model human gliomagenesis using&#xD;
      3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells&#xD;
      (hiPSCs).&#xD;
&#xD;
      The working hypothesis is that 3D brain organoids can develop glioma-like structures and&#xD;
      recapitulate phenotypic traits of gliomas when generated from hiPSCs expressing genetic&#xD;
      mutants associated with glioma predisposition.&#xD;
&#xD;
      Methodology : To develop this pioneer study on the use of hiPSC-based brain organoids as a&#xD;
      strategy to model gliomagenesis and study the impact of genetic mutants, it will be collect&#xD;
      the peripheral blood mononuclear cell from 20 patients with high grade astrocytoma with or&#xD;
      without IDH mutation. iPS will be generated from these PBMC and will be genetically modified&#xD;
      according to different mutations. Then, it will be generate brain organoids according to&#xD;
      standard protocols. Brain organoids generated from all different cells will be collected at&#xD;
      different time points and analyzed for the presence of glioma-like structures and phenotypic&#xD;
      hallmarks of gliomas.&#xD;
&#xD;
      From the proposed experiments, it will be expect that brain organoids will develop&#xD;
      glioma-like features upon the presence of genetic mutations. Thus, it will be expect to&#xD;
      demonstrate that brain organoids can be used as a reliable strategy to test the impact of&#xD;
      genetic mutants, including the possible synergistic cooperation between different mutations&#xD;
      on early gliomagenic events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">June 7, 2019</start_date>
  <completion_date type="Anticipated">December 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the level of proliferation of organoids</measure>
    <time_frame>18 months</time_frame>
    <description>compare different immunohistochemical markings between organoids</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Patient with high grade astrocytoma</arm_group_label>
    <description>Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).</description>
    <arm_group_label>Patient with high grade astrocytoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients managed for a brain tumor for whom a blood sample collected routinely will be&#xD;
        recovered&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female, aged 18 years or older&#xD;
&#xD;
          -  Astrocytoma grades 3 or 4, confirmed by anatomopathological diagnosis&#xD;
&#xD;
          -  Patient having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person in emergency situation, a legal person of legal age (guardianship, guardianship&#xD;
             or legal guardianship), or unable to express his / her consent&#xD;
&#xD;
          -  No affiliation to a social security scheme (beneficiary or beneficiary)&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emeline TABOURET, PH</last_name>
    <phone>491385500</phone>
    <phone_ext>+33</phone_ext>
    <email>emeline.tabouret@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique FIGARELLA, PUPH</last_name>
    <phone>413429011</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.figarella-branger@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emeline TABOURET, PH</last_name>
      <phone>491385500</phone>
      <phone_ext>+33</phone_ext>
      <email>emeline.tabouret@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Emeline TABOURET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

